Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28015870 | 0.82 | MDM4 (0.56) | MDM4TP53MDM2 | |
| SCHEMBL30600490 | 0.82 | MDM4 (0.56) | MDM4TP53MDM2 | |
| SCHEMBL17269327 | 0.82 | MDM4 (0.56) | MDM4TP53MDM2 | |
| SCHEMBL20677239 | 0.82 | MDM4 (0.56) | MDM4TP53MDM2 | |
| SCHEMBL15164253 | 0.77 | MDM4 (0.48) | MDM4TP53MDM2 | |
| SCHEMBL27890071 | 0.77 | MDM4 (0.49) | MDM4TP53MDM2 | |
| SCHEMBL20106639 | 0.76 | MDM4 (0.47) | MDM4TP53 | |
| SCHEMBL31634371 | 0.74 | MDM2 (0.50) | MDM4TP53MDM2PRCP | |
| SCHEMBL38654696 | 0.73 | MGAM (0.47) | MDM4TP53 | |
| SCHEMBL14614452 | 0.71 | REN (0.41) | MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016301-A1 | Synthesis of Beta-Arrestin Effectors | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2018-01-18 | — | — | US | disclosed |
| US-9611293-B2 | Synthesis of beta-arrestin effectors | TREVENA, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20150329593-A1 | Synthesis of Beta-Arrestin Effectors | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016301-A1 | Synthesis of Beta-Arrestin Effectors | ARRB1, ADRB1, ADRB3 | MDM4 4169/4885TP53 3872/4885MDM2 1072/4885 |
| US-20150329593-A1 | Synthesis of Beta-Arrestin Effectors | ARRB1, ADRB1, ADRB3 | MDM4 4169/4885TP53 3872/4885MDM2 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.